Home > Search Results: Siu, L L.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.01 seconds.
Articles, 3 records found
Articles 3 records found  
1.
11 p, 877.0 KB Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma : Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy / Zandberg, Dan P. (University of Pittsburgh Medical Center. Hillman Cancer Center) ; Algazi, Alain P. (University of California San Francisco Helen Diller Family Comprehensive Cancer Center) ; Jimeno, Antonio (Division of Medical Oncology. University of Colorado School of Medicine) ; Good, James S. (Institute of Head and Neck Studies and Education. Queen Elizabeth Hospital) ; Fayette, Jérôme (Clinical Oncology. Cancer Center Centre Léon Bérard. University of Lyon) ; Bouganim, Nathaniel (Department of Oncology. McGill University Health Centre) ; Ready, Neal E. (Duke University Medical Center) ; Clement, Paul M. (Department of Oncology. Leuven Cancer Institute) ; Even, Caroline (Institut Gustave Roussy (Villejuif, França)) ; Jang, Raymond W. (Princess Margaret Cancer Centre. University of Toronto) ; Wong, Stuart (Division of Hematology Oncology. Medical College of Wisconsin) ; Keilholz, Ulrich (Charité Comprehensive Cancer Center) ; Gilbert, Jill (Henry-Joyce Cancer Clinic) ; Fenton, Moon (The West Cancer Center. University of Tennessee Health Science Center) ; Braña, Irene (Vall d'Hebron Institut d'Oncologia) ; Henry, Stephanie (Department of Oncology-Hematology. Radiotherapy. and Nuclear Medicine. CHU UCL Namur) ; Remenar, Eva (National Institute of Oncology (Országos Onkológiai Intézet)) ; Papai, Zsuzsanna (State Health. Center Higatian Defanse Forses) ; Siu, Lillian L. (Princess Margaret Cancer Centre. University of Toronto) ; Jarkowski, Anthony (AstraZeneca) ; Armstrong, Jon M. (AstraZeneca) ; Asubonteng, Kobby (AstraZeneca) ; Fan, Jean (AstraZeneca) ; Melillo, Giovanni (AstraZeneca) ; Mesía, Ricard (Institut d'Investigació Biomèdica de Bellvitge) ; Universitat Autònoma de Barcelona
Background: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited therapeutic options. Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) are frequently upregulated in HNSCC. [...]
2019 - 10.1016/j.ejca.2018.11.015
European journal of cancer, Vol. 107 (january 2019) , p. 142-152  
Detailed record - Creative Commons
2.
11 p, 927.9 KB A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer / Wainberg, Zev A. (David Geffen School of Medicina, UCLA (USA)) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Soares, Heloisa P. (Moffitt Cancer Center (USA)) ; Braña, Irene (Princess Margaret Cancer Centre (Canada)) ; Britten, Carolyn D. (Medical University of South Carolina (USA)) ; Del Conte, Gianluca (IRCCS Ospedale San Raffaele(Italy)) ; Ezeh, Patrick (Pfizer Oncology (USA)) ; Houk, Brett (Pfizer Oncology (USA)) ; Kern, Kenneth A. (Pfizer Oncology (USA)) ; Leong, Stephen (University of Colorado (USA)) ; Pathan, Nuzhat (Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121 USA) ; Pierce, Kristen J. (Pfizer Oncology (USA)) ; Siu, Lillian L. (Princess Margaret Cancer Centre (Canada)) ; Vermette, Jennifer (Pfizer Oncology (USA)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. [...]
2017 - 10.1007/s11523-017-0530-5
Targeted Oncology, Vol. 12, Issue 6 (December 2017) , p. 775-785  
Detailed record - Creative Commons
3.
10 p, 426.6 KB A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies / Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Delord, Jean-Pierre (Institut Claudius Regaud (France)) ; Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ; Berge, Y. (Institut Claudius Regaud (France)) ; Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ; Cottura, E. (Institut Claudius Regaud (France)) ; Bedard, Philippe L (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Akimov, Mikhail (Novartis Pharma AG (Switzerland)) ; Lu, H. (Novartis Pharmaceuticals Corp (USA)) ; Pain, S. (Novartis Pharmaceuticals Corp (USA)) ; Kaag, A. (Novartis Pharma AG (Switzerland)) ; Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659  
Detailed record - Creative Commons

See also: similar author names
2 Siu, L. L.
1 Siu, Lillian L
2 Siu, Lillian L.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with